INNOVAGE HLDG DL -,001

At the Wells Fargo Healthcare Conference InnovAge presented the completion of its restructuring and its focus on operational optimization. For fiscal 2026 the company reported adjusted EBITDA of $95 million and expects $105–115 million for 2027, despite a less favorable reimbursement environment. Management cites organic growth, regulatory modernization, and expansion into adjacent target groups as main growth paths and emphasizes selective use of AI to boost efficiency. The stock rose about 8.7% in premarket trading and is approaching its 52-week high. » More on de.investing.com

InnovAge reported a normalized EBITDA increase of about 175% to $94.6 million for fiscal 2026 and revenue growth of 15.9% to $989.7 million. Net loss narrowed to $0.7 million versus $35.3 million a year earlier; management cited one-time legal provisions as a drag. For 2027 InnovAge forecasts revenue of $1.05–1.085 billion and normalized EBITDA of $105–115 million, which should further expand margins. CEO Patrick Blair announced a new growth phase focused on technology, AI integration and potential acquisitions, prompting a strong premarket jump in the stock to near its 52-week high. » More on de.investing.com

InnovAge reported adjusted EBITDA of $94.6 million for fiscal 2026 (≈+175%) on revenue of $989.7 million (+15.9%) and reduced its net loss to $0.7 million. The EBITDA margin rose to 9.6% and membership grew to about 8,230. For 2027 management expects revenue of $1.05–1.085 billion and adjusted EBITDA of $105–115 million. The shares reacted positively after hours and climbed sharply as investors welcomed the improved profitability and outlook. » More on de.investing.com